Dasabuvir (ABT-333)

Dasabuvir (ABT-333) (CAS No.: 1132935-63-7) is a synthetic small molecule classified as a direct acting antiviral research tool and non nucleoside inhibitor of the hepatitis C virus NS5B RNA dependent RNA polymerase, and it is primarily used in virology and drug discovery workflows to investigate viral RNA replication biology, polymerase inhibition pharmacology, and resistance associated sequence variation in genotype specific systems; mechanistically, it binds an allosteric region of NS5B rather than the nucleotide catalytic site, thereby suppressing polymerase function and reducing viral RNA synthesis in HCV genotype 1 replicon and recombinant enzyme platforms, with reported inhibitory potency in the low nanomolar range across genotype 1a and 1b contexts and strong selectivity over mammalian polymerases, supporting its value for target validation and structure activity relationship studies in selective antiviral lead profiling; in experimental practice, this compound is commonly incorporated into biochemical polymerase assays, subgenomic replicon cell models, combination interaction studies with other antiviral classes, and preclinical antiviral screening cascades designed to map mechanism linked efficacy and resistance barriers, while the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.